Santosh Prasad Chaudhary Kurmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Santosh Prasad Chaudhary Kurmi has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Shankar Thapa
Department of Pharmacy, Madan Bhandari Academy of Health Sciences, Hetauda, Nepal
5 shared publications - Sadik Shaik
Department of Pharmacology Anuradha College of Pharmacy Bengaluru India
2 shared publications Sibghatullah Muhammad Ali Sangi
Basic Medical Sciences Department, Dar Al Uloom University, College of Medicine, Riyadh, Saudi Arabia
2 shared publicationsSreeharsha Nagaraja
King Faisal University
2 shared publicationsAbhishek Chowdhury
Department of Chemistry, Faculty of Science, Sam Higginbottom University of Agriculture, Technology and Sciences (SHUATS), Prayagraj, India
1 shared publication- Ammar Abdul Razzak Mahmood
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by SAGE Publications in Bioinformatics and Biology Insights
- Vol. 20
In Silico Identification of Lepiotaprocerin C as a Promising PIM-1 Kinase Inhibitor: An Integrated Docking, Molecular Dynamics, MM/PBSA, QSAR, and ADMET Study
Proviral Integration site for Moloney murine leukemia virus-1 (PIM-1) kinase, a serine/threonine kinase overexpressed in various malignancies, plays a critical role in promoting cell survival and proliferation, making it a promising target for anticancer therapy. This study employed an integrated in silico approach to evaluate Lepiotaprocerin derivatives (A to L) from Macrolepiota procera as potential PIM-1 inhibitors. Molecular docking of 12 Lepiotaprocerins revealed Lepiotaprocerin C as the most potent compound, exhibiting superior binding affinity (−11.4 kcal/mol) compared with the reference inhibitor AZD1208. Binding site validation using CASTp, PrankWeb, and blind docking confirmed the ATP-binding pocket as the active cavity. The Lepiotaprocerin C-PIM-1 complex demonstrated enhanced stability during 200 ns molecular dynamics simulations, maintaining low RMSD and strong hydrogen-bond interactions, supported by a favorable Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) binding free energy (−22.0 ± 2.1 kcal/mol). Based on quantitative structure activity relationship (QSAR) analysis, the calculated pIC 50 value of Lepiotaprocerin C was 8.67. QSAR modeling ( R 2 = .74, Q 2 = 0.90) confirmed robust predictive capacity, while absorption, distribution, metabolism, and elimination and PerMM analysis indicated favorable pharmacokinetic and permeability profiles. Prediction of Activity Spectra for Substances and toxicity predictions further revealed high antineoplastic potential (Pa = 0.881) and a nontoxic safety profile. These results highlight Lepiotaprocerin C as a promising, stable, and safe inhibitor of PIM-1 kinase, warranting further in vitro and in vivo validation for potential anticancer drug development.
- 12 January 2026
- Published by SAGE Publications in Bioinformatics and Biology Insights
- Vol. 20
Open AccessIn Silico Identification of Lepiotaprocerin C as a Promising PIM-1 Kinase Inhibitor: An Integrated Docking, Molecular Dynamics, MM/PBSA, QSAR, and ADMET Study
Proviral Integration site for Moloney murine leukemia virus-1 (PIM-1) kinase, a serine/threonine kinase overexpressed in various malignancies, plays a critical role in promoting cell survival and proliferation, making it a promising target for anticancer therapy. This study employed an integrated in silico approach to evaluate Lepiotaprocerin derivatives (A to L) from Macrolepiota procera as potential PIM-1 inhibitors. Molecular docking of 12 Lepiotaprocerins revealed Lepiotaprocerin C as the most potent compound, exhibiting superior binding affinity (−11.4 kcal/mol) compared with the reference inhibitor AZD1208. Binding site validation using CASTp, PrankWeb, and blind docking confirmed the ATP-binding pocket as the active cavity. The Lepiotaprocerin C-PIM-1 complex demonstrated enhanced stability during 200 ns molecular dynamics simulations, maintaining low RMSD and strong hydrogen-bond interactions, supported by a favorable Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) binding free energy (−22.0 ± 2.1 kcal/mol). Based on quantitative structure activity relationship (QSAR) analysis, the calculated pIC 50 value of Lepiotaprocerin C was 8.67. QSAR modeling ( R 2 = .74, Q 2 = 0.90) confirmed robust predictive capacity, while absorption, distribution, metabolism, and elimination and PerMM analysis indicated favorable pharmacokinetic and permeability profiles. Prediction of Activity Spectra for Substances and toxicity predictions further revealed high antineoplastic potential (Pa = 0.881) and a nontoxic safety profile. These results highlight Lepiotaprocerin C as a promising, stable, and safe inhibitor of PIM-1 kinase, warranting further in vitro and in vivo validation for potential anticancer drug development.
- Open Access
- 6 January 2026
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 27 (1)
Integrated in silico and in vitro evaluation of Genistein and Apigenin as dual inhibitors of PARP1 and ESR1 in breast cancer
Breast cancer remains a leading cause of cancer-related mortality among women worldwide, highlighting the need for safer multitarget therapies. Genistein (
- 6 January 2026
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 27 (1)
Open AccessIntegrated in silico and in vitro evaluation of Genistein and Apigenin as dual inhibitors of PARP1 and ESR1 in breast cancer
Breast cancer remains a leading cause of cancer-related mortality among women worldwide, highlighting the need for safer multitarget therapies. Genistein (
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Chemistry
- Vol. 2026 (1) , 2211953
Computational Exploration of Biphenyl Derivatives as PD‐L1 Inhibitors for TNBC Using Docking, Molecular Dynamics, MM‐GBSA, DFT, and AI/ML‐Based QSAR Modeling
Triple negative breast cancer (TNBC) remains a leading cause of cancer‐related mortality among women, creating an urgent need for new therapeutic strategies. This study aims to design potential PD‐L1 inhibitors using an in silico approach, integrating molecular docking with quantitative structure–activity relationship (QSAR) modeling in the discovery of promising candidates for immunotherapy in TNBC. Around 12 compounds were selected based on binding affinity equal to or greater than 9.5 kcal/mol. Binding analysis was done to select a lead compound. The reference ligand exhibited a binding affinity of −7.1 kcal/mol at the PD‐1/PD‐L1 interface, whereas the selected compound 3 with improved binding affinity (−13.4 kcal/mol) showed key interactions with critical residues Tyr56, Met115, Ala121, and Asp122, suggesting a comparatively stronger predicted binding affinity toward the PD‐L1 interface relative to the reference compound, within the limitations of docking‐based evaluation. The compound 3‐7DY7 complex demonstrated enhanced stability during 100 ns molecular dynamics (MD) simulations, maintaining low RMSD and strong hydrogen–bond interactions, supported by a favorable MM‐GBSA binding free energy (−118.994 kcal/mol). Compound 3 exhibited a slightly higher HOMO energy (−0.184 eV) compared to reference (−0.219 eV), indicating a greater ability to donate electrons. Consequently, compound 3 also showed a higher nucleophilicity index ( N = 8.935 eV), suggesting that it is more susceptible to electrophilic attack. Based on the QSAR analysis, the calculated pIC 50 value of compound 3 was 8.8. The QSAR modeling ( R 2 = 0.974, RMSE = 0.244, MAE = 0.167) confirmed robust predictive capacity. These results highlight compound 3 as a promising inhibitor of PDL‐1. This candidate could be prioritized for subsequent chemical synthesis and in vitro bioassays to confirm the computational findings.
- 1 January 2026
- Published by Wiley in Journal of Chemistry
- Vol. 2026 (1) , 2211953
Open AccessComputational Exploration of Biphenyl Derivatives as PD‐L1 Inhibitors for TNBC Using Docking, Molecular Dynamics, MM‐GBSA, DFT, and AI/ML‐Based QSAR Modeling
Triple negative breast cancer (TNBC) remains a leading cause of cancer‐related mortality among women, creating an urgent need for new therapeutic strategies. This study aims to design potential PD‐L1 inhibitors using an in silico approach, integrating molecular docking with quantitative structure–activity relationship (QSAR) modeling in the discovery of promising candidates for immunotherapy in TNBC. Around 12 compounds were selected based on binding affinity equal to or greater than 9.5 kcal/mol. Binding analysis was done to select a lead compound. The reference ligand exhibited a binding affinity of −7.1 kcal/mol at the PD‐1/PD‐L1 interface, whereas the selected compound 3 with improved binding affinity (−13.4 kcal/mol) showed key interactions with critical residues Tyr56, Met115, Ala121, and Asp122, suggesting a comparatively stronger predicted binding affinity toward the PD‐L1 interface relative to the reference compound, within the limitations of docking‐based evaluation. The compound 3‐7DY7 complex demonstrated enhanced stability during 100 ns molecular dynamics (MD) simulations, maintaining low RMSD and strong hydrogen–bond interactions, supported by a favorable MM‐GBSA binding free energy (−118.994 kcal/mol). Compound 3 exhibited a slightly higher HOMO energy (−0.184 eV) compared to reference (−0.219 eV), indicating a greater ability to donate electrons. Consequently, compound 3 also showed a higher nucleophilicity index ( N = 8.935 eV), suggesting that it is more susceptible to electrophilic attack. Based on the QSAR analysis, the calculated pIC 50 value of compound 3 was 8.8. The QSAR modeling ( R 2 = 0.974, RMSE = 0.244, MAE = 0.167) confirmed robust predictive capacity. These results highlight compound 3 as a promising inhibitor of PDL‐1. This candidate could be prioritized for subsequent chemical synthesis and in vitro bioassays to confirm the computational findings.
- Open Access
- 8 December 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (12)
Repurposing Simvastatin and Lovastatin for Colorectal Cancer: An Integrated in-Silico and in-Vitro Study
Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Statins, widely prescribed lipid-lowering agents, have been suggested to possess anticancer activity; however, their precise mechanisms in CRC remain poorly defined. Methods: This study employed an integrated in silico–in vitro approach to investigate the therapeutic potential of Simvastatin and Lovastatin in CRC. Network pharmacology analysis identified hub genes linking the mevalonate pathway, lipid biosynthesis, and apoptosis regulation. Molecular docking was performed to assess binding affinities, followed by molecular dynamics (MD) simulations and MM-PBSA free energy calculations for stability and binding strength evaluation. In vitro cytotoxicity was validated using HCT116 and HT-29 colorectal cancer cell lines. Results: Five hub genes (HMGCR, CYP51A1, FDFT1, SCD, and LCK) were identified as key targets. Docking studies revealed strong binding affinities, with scores of −8.4 kcal·mol −1 for Simvastatin–3LCK, −9.5 kcal·mol −1 for Lovastatin–3WEG, and −9.4 kcal·mol −1 for Lovastatin–8SBI complexes. MD simulations indicated stable binding of Simvastatin with 3LCK, characterized by minimal RMSD and SASA fluctuations, whereas Lovastatin displayed higher flexibility. MM-PBSA analysis demonstrated robust binding free energies for Lovastatin–3WEG (–64.73 kcal·mol −1 ) and Simvastatin–3LCK (–56.47 kcal·mol −1 ). In vitro assays confirmed a dose-dependent reduction in cell viability, with IC 50 values of 8.9 ± 0.17 μM (Simvastatin) and 12.6 ± 0.32 μM (Lovastatin) in HCT116, compared with 14.4 ± 0.15 μM and 18.7 ± 0.53 μM in HT-29 cells, respectively. Conclusion: This integrated study demonstrates that Simvastatin and Lovastatin exert cytotoxic effects in CRC cells by targeting metabolic and apoptotic pathways. Simvastatin showed superior activity compared with Lovastatin.
- 8 December 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (12)
Open AccessRepurposing Simvastatin and Lovastatin for Colorectal Cancer: An Integrated in-Silico and in-Vitro Study
Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Statins, widely prescribed lipid-lowering agents, have been suggested to possess anticancer activity; however, their precise mechanisms in CRC remain poorly defined. Methods: This study employed an integrated in silico–in vitro approach to investigate the therapeutic potential of Simvastatin and Lovastatin in CRC. Network pharmacology analysis identified hub genes linking the mevalonate pathway, lipid biosynthesis, and apoptosis regulation. Molecular docking was performed to assess binding affinities, followed by molecular dynamics (MD) simulations and MM-PBSA free energy calculations for stability and binding strength evaluation. In vitro cytotoxicity was validated using HCT116 and HT-29 colorectal cancer cell lines. Results: Five hub genes (HMGCR, CYP51A1, FDFT1, SCD, and LCK) were identified as key targets. Docking studies revealed strong binding affinities, with scores of −8.4 kcal·mol −1 for Simvastatin–3LCK, −9.5 kcal·mol −1 for Lovastatin–3WEG, and −9.4 kcal·mol −1 for Lovastatin–8SBI complexes. MD simulations indicated stable binding of Simvastatin with 3LCK, characterized by minimal RMSD and SASA fluctuations, whereas Lovastatin displayed higher flexibility. MM-PBSA analysis demonstrated robust binding free energies for Lovastatin–3WEG (–64.73 kcal·mol −1 ) and Simvastatin–3LCK (–56.47 kcal·mol −1 ). In vitro assays confirmed a dose-dependent reduction in cell viability, with IC 50 values of 8.9 ± 0.17 μM (Simvastatin) and 12.6 ± 0.32 μM (Lovastatin) in HCT116, compared with 14.4 ± 0.15 μM and 18.7 ± 0.53 μM in HT-29 cells, respectively. Conclusion: This integrated study demonstrates that Simvastatin and Lovastatin exert cytotoxic effects in CRC cells by targeting metabolic and apoptotic pathways. Simvastatin showed superior activity compared with Lovastatin.
- Open Access
- 20 November 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (11)
LC-MS Profiling and Anti-Inflammatory Activity of Saurauia fasciculata Bark: Network Pharmacology, Molecular Docking, MD Simulation, and in-Vitro Validation
Background: Saurauia fasciculata has been traditionally utilized in Nepalese medicine for various therapeutic applications. This study aimed to characterize the phytochemical profile and evaluate the anti-inflammatory potential of S. fasciculata bark extract using an integrated in-silico and in-vitro approach. Methods: Methanolic bark extract was prepared by sequential maceration and analyzed using Fourier transform infrared spectroscopy (FT-IR) for functional group characterization and liquid chromatography–mass spectrometry (LC–MS/MS) for phytochemical profiling. Network pharmacology analysis was performed to predict inflammation-related targets. Key protein targets (PIK3R1 and PIK3CA) were subjected to molecular docking (AutoDock Vina v1.2.0) with identified phytoconstituents, followed by 100 ns molecular dynamics simulations using Schrödinger Desmond (release 2022-3). Post-simulation analysis was performed to validate the complex stability. Pharmacokinetic properties of the top phytoconstituents were evaluated in silico. Anti-inflammatory potential of the crude extract was validated in vitro using the protein denaturation assay, with aspirin as the standard. Results: LC–MS analysis revealed multiple bioactive constituents, including Equol, 2′-methoxy-6,8-dimethyl flavone, Quercetin, Retusin, and Corosolic acid. Network pharmacology highlighted PIK3R1 and PIK3CA as pivotal inflammation-related targets. Molecular docking showed that Equol had the highest binding affinity toward PIK3-δ (6PYR; −9.0 kcal/mol) and PIK3-α (8EXL; −9.1 kcal/mol). MD simulations confirmed stable protein–ligand interactions, and PCA and MM/GBSA analyses supported strong binding stability and energetics. In vitro, the extract inhibited protein denaturation in a dose-dependent manner, with an IC 50 of 112.10 ± 0.57 µg/mL compared to 75.33 ± 0.73 µg/mL for aspirin, suggesting moderate anti-inflammatory activity. Conclusion: This study provides preliminary evidence supporting the anti-inflammatory potential of S. fasciculata bark extract, with Equol identified as a promising candidate for further investigation.
- 20 November 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (11)
Open AccessLC-MS Profiling and Anti-Inflammatory Activity of Saurauia fasciculata Bark: Network Pharmacology, Molecular Docking, MD Simulation, and in-Vitro Validation
Background: Saurauia fasciculata has been traditionally utilized in Nepalese medicine for various therapeutic applications. This study aimed to characterize the phytochemical profile and evaluate the anti-inflammatory potential of S. fasciculata bark extract using an integrated in-silico and in-vitro approach. Methods: Methanolic bark extract was prepared by sequential maceration and analyzed using Fourier transform infrared spectroscopy (FT-IR) for functional group characterization and liquid chromatography–mass spectrometry (LC–MS/MS) for phytochemical profiling. Network pharmacology analysis was performed to predict inflammation-related targets. Key protein targets (PIK3R1 and PIK3CA) were subjected to molecular docking (AutoDock Vina v1.2.0) with identified phytoconstituents, followed by 100 ns molecular dynamics simulations using Schrödinger Desmond (release 2022-3). Post-simulation analysis was performed to validate the complex stability. Pharmacokinetic properties of the top phytoconstituents were evaluated in silico. Anti-inflammatory potential of the crude extract was validated in vitro using the protein denaturation assay, with aspirin as the standard. Results: LC–MS analysis revealed multiple bioactive constituents, including Equol, 2′-methoxy-6,8-dimethyl flavone, Quercetin, Retusin, and Corosolic acid. Network pharmacology highlighted PIK3R1 and PIK3CA as pivotal inflammation-related targets. Molecular docking showed that Equol had the highest binding affinity toward PIK3-δ (6PYR; −9.0 kcal/mol) and PIK3-α (8EXL; −9.1 kcal/mol). MD simulations confirmed stable protein–ligand interactions, and PCA and MM/GBSA analyses supported strong binding stability and energetics. In vitro, the extract inhibited protein denaturation in a dose-dependent manner, with an IC 50 of 112.10 ± 0.57 µg/mL compared to 75.33 ± 0.73 µg/mL for aspirin, suggesting moderate anti-inflammatory activity. Conclusion: This study provides preliminary evidence supporting the anti-inflammatory potential of S. fasciculata bark extract, with Equol identified as a promising candidate for further investigation.
- Open Access
- 25 September 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (9)
Phytochemical Fingerprinting and Cytotoxic Insight: HPTLC Quantification and Validation of Ascorbic Acid in Adansonia digitata with MCF-7 Cell Evaluation
Background: Adansonia digitata (Baobab) is a nutrient-dense medicinal plant valued for its therapeutic properties, particularly its rich content of ascorbic acid. Accurate quantification of ascorbic acid is crucial for standardizing its extracts and evaluating their biological activities. Methods: A specific and robust high-performance thin-layer chromatography (HPTLC) method was developed and validated for the quantitative determination of ascorbic acid in A. digitata fruit extract. Method validation was carried out in accordance with ICH Q2(R1) guidelines, assessing parameters such as system suitability, linearity, precision, accuracy, sensitivity (LOD and LOQ), and robustness. Additionally, its cytotoxic potential against MCF-7 breast cancer cells was evaluated. Results: The HPTLC method demonstrated excellent linearity (R 2 = 0.999) across 500–2500 µg/spot, with high precision (%RSD < 2%), accuracy (mean recovery 100.82%), and robustness. The method's sensitivity was supported by low LOD (39 µg/spot) and LOQ (500 µg/spot). Cytotoxicity analysis using MTT assay revealed dose-dependent inhibition of MCF-7 cell viability, with an IC 50 of 27.90 µg/mL, suggesting moderate anticancer potential. Conclusion: The validated HPTLC method offers a simple, precise, and reproducible approach for quantifying ascorbic acid in A. digitata fruit extract, supporting its standardization and potential application in quality control of herbal formulations and nutraceuticals.
- 25 September 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (9)
Open AccessPhytochemical Fingerprinting and Cytotoxic Insight: HPTLC Quantification and Validation of Ascorbic Acid in Adansonia digitata with MCF-7 Cell Evaluation
Background: Adansonia digitata (Baobab) is a nutrient-dense medicinal plant valued for its therapeutic properties, particularly its rich content of ascorbic acid. Accurate quantification of ascorbic acid is crucial for standardizing its extracts and evaluating their biological activities. Methods: A specific and robust high-performance thin-layer chromatography (HPTLC) method was developed and validated for the quantitative determination of ascorbic acid in A. digitata fruit extract. Method validation was carried out in accordance with ICH Q2(R1) guidelines, assessing parameters such as system suitability, linearity, precision, accuracy, sensitivity (LOD and LOQ), and robustness. Additionally, its cytotoxic potential against MCF-7 breast cancer cells was evaluated. Results: The HPTLC method demonstrated excellent linearity (R 2 = 0.999) across 500–2500 µg/spot, with high precision (%RSD < 2%), accuracy (mean recovery 100.82%), and robustness. The method's sensitivity was supported by low LOD (39 µg/spot) and LOQ (500 µg/spot). Cytotoxicity analysis using MTT assay revealed dose-dependent inhibition of MCF-7 cell viability, with an IC 50 of 27.90 µg/mL, suggesting moderate anticancer potential. Conclusion: The validated HPTLC method offers a simple, precise, and reproducible approach for quantifying ascorbic acid in A. digitata fruit extract, supporting its standardization and potential application in quality control of herbal formulations and nutraceuticals.
- Open Access
- 22 August 2025
- Published by SAGE Publications in Bioinformatics and Biology Insights
- Vol. 19
Repurposing terfenadine and domperidone for inhibition of apoptotic gene association in colorectal cancer: A system pharmacology approach integrated with molecular docking, MD simulations, and post-MD simulation analysis
Colorectal cancer (CRC) remains a leading cause of global cancer mortality, underscoring the need for novel therapeutic strategies. This study used a systems pharmacology approach integrated with molecular docking and molecular dynamics (MD) simulations to evaluate the potential of repurposing terfenadine and domperidone for inhibition of apoptotic gene associations in CRC. Network pharmacology analysis identified 4 principal targets—SLC6A4 (5I6X), DRD2 (7DFP), HTR2A (6WGT), and EGFR (6LUD)—involved in the apoptotic regulatory network. Molecular docking studies demonstrated high binding affinities of both terfenadine and domperidone against all selected targets (−7.1 to −11.5 kcal/mol), with the strongest interaction observed with DRD2, where both compounds exhibited a binding affinity of −11.5 kcal/mol. Detailed interaction profiling revealed critical hydrogen bonding and hydrophobic interactions stabilizing the drug-target complexes. Molecular dynamics simulations over a 100 ns timescale confirmed the structural stability and conformational fidelity of the docked complexes, evidenced by low root mean square deviation values and consistent hydrogen bond occupancy. Furthermore, post-MD simulation study supports the stable score landscape and stability of complex. In conclusion, this integrative computational analysis highlights terfenadine and domperidone as promising candidates capable of modulating key apoptotic pathways in CRC. The findings provide a strong rationale for subsequent in vitro and in vivo studies to validate their therapeutic potential and facilitate clinical translation in CRC management.
- 22 August 2025
- Published by SAGE Publications in Bioinformatics and Biology Insights
- Vol. 19
Open AccessRepurposing terfenadine and domperidone for inhibition of apoptotic gene association in colorectal cancer: A system pharmacology approach integrated with molecular docking, MD simulations, and post-MD simulation analysis
Colorectal cancer (CRC) remains a leading cause of global cancer mortality, underscoring the need for novel therapeutic strategies. This study used a systems pharmacology approach integrated with molecular docking and molecular dynamics (MD) simulations to evaluate the potential of repurposing terfenadine and domperidone for inhibition of apoptotic gene associations in CRC. Network pharmacology analysis identified 4 principal targets—SLC6A4 (5I6X), DRD2 (7DFP), HTR2A (6WGT), and EGFR (6LUD)—involved in the apoptotic regulatory network. Molecular docking studies demonstrated high binding affinities of both terfenadine and domperidone against all selected targets (−7.1 to −11.5 kcal/mol), with the strongest interaction observed with DRD2, where both compounds exhibited a binding affinity of −11.5 kcal/mol. Detailed interaction profiling revealed critical hydrogen bonding and hydrophobic interactions stabilizing the drug-target complexes. Molecular dynamics simulations over a 100 ns timescale confirmed the structural stability and conformational fidelity of the docked complexes, evidenced by low root mean square deviation values and consistent hydrogen bond occupancy. Furthermore, post-MD simulation study supports the stable score landscape and stability of complex. In conclusion, this integrative computational analysis highlights terfenadine and domperidone as promising candidates capable of modulating key apoptotic pathways in CRC. The findings provide a strong rationale for subsequent in vitro and in vivo studies to validate their therapeutic potential and facilitate clinical translation in CRC management.